Literature DB >> 8866630

Microinjection technique for pharmacological evaluation of microvascular permeability in human skin.

I Herrig1, U Hoffmann, M Fischer, U K Franzeck, A Bollinger.   

Abstract

A new technique which combines skin microinjection of minute amounts of drugs (0.5 microliter) and measurement of capillary permeability by intravital fluorescence videomicroscopy and densitometry is introduced. Glass micropipettes with a tip diameter of 7-9 microns are inserted by a micromanipulator into the stratum papillare containing the capillary loops and used for microinjection by microsyringe and special dispenser. Transcapillary diffusion of sodium fluorescein applied by intravenous bolus injection is visualised by fluorescence videomicroscopy and stored on videotape. Perivascular fluorescent light intensity (FLI) is measured in arbitrary units (AU) by videodensitometry around the site of microinjection during playback of the videotapes. The method was tested by microinjection of 0.5 microliter histamine (1% solution) at the distal tibial plateau. Mean FLI values representing microvascular permeability were 2186 AU 10 min after microinjection of histamine, 420 AU after physiologic saline and 1228 AU after histamine combined with oral intake of 20 mg cetirizine. Cetirizine significantly reduced (P < 0.01) the increased permeability induced by histamine. However, the mean values after injection of the H1-blocker were still significantly enhanced (P < 0.01) when compared to the mean values observed after injection of physiologic saline solution, which provoked only minor microtrauma. The technique offers new scope for pharmacological testing in man.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866630     DOI: 10.1007/bf00203779

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  The nature of the vaso-dilator constituents of certain tissue extracts.

Authors:  C H Best; H H Dale; H W Dudley; W V Thorpe
Journal:  J Physiol       Date:  1927-03-15       Impact factor: 5.182

2.  The physiological action of beta-iminazolylethylamine.

Authors:  H H Dale; P P Laidlaw
Journal:  J Physiol       Date:  1910-12-31       Impact factor: 5.182

3.  Quantitative time course study of the skin response to histamine and the effect of H1 blockers. A 3-week crossover double-blind comparative trial of cetirizine and terfenadine.

Authors:  J P Rihoux; D J Van Neste
Journal:  Dermatologica       Date:  1989

4.  Diffusion, pericapillary distribution and clearance of Na-fluorescein in the human nailfold.

Authors:  A Bollinger; K Jäger; A Roten; C Timeus; F Mahler
Journal:  Pflugers Arch       Date:  1979-11       Impact factor: 3.657

5.  [A device for dynamic intravital videomicroscopy].

Authors:  U K Franzeck; G Isenring; J Frey; K Jäger; F Mahler; A Bollinger
Journal:  Vasa       Date:  1983       Impact factor: 1.961

6.  Blood volume measurement: a critical study prediction of normal values: controlled measurement of sequential changes: choice of a bedside method.

Authors:  F J Dagher; J H Lyons; D C Finlayson; J Shamsai; F D Moore
Journal:  Adv Surg       Date:  1965

7.  Diameter, thickness, area, and volume of skin-prick histamine weals. Measurement of skin thickness by 15 MHz A-mode ultrasound.

Authors:  J Serup
Journal:  Allergy       Date:  1984-07       Impact factor: 13.146

8.  Transcapillary diffusion of Na-fluorescein measured by a 'large window technique' in skin areas of the forefoot.

Authors:  C Baer-Suryadinata; A Bollinger
Journal:  Int J Microcirc Clin Exp       Date:  1985

9.  The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine.

Authors:  F M Gengo; J Dabronzo; A Yurchak; S Love; J K Miller
Journal:  Clin Pharmacol Ther       Date:  1987-09       Impact factor: 6.875

10.  Patterns of diffusion through skin capillaries in patients with long-term diabetes.

Authors:  A Bollinger; J Frey; K Jäger; J Furrer; J Seglias; W Siegenthaler
Journal:  N Engl J Med       Date:  1982-11-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.